CAJ | 학술논문

过去的几年里，绝经后骨质疏松领域有了一些重要的研究发现。长期持续的双膦酸盐类药物治疗会提高患者非典型股骨骨折的风险。在骨折高风险的绝经后患者中，特立帕肽和狄诺塞麦联合治疗组与两药分别单用组相比，联合治疗组患者的骨密度明显增加。目前，一些治疗骨质疏松新的策略正处于不同的研究阶段，如组织蛋白酶K抑制剂、重组甲状旁腺激素。
과거적궤년리，절경후골질소송영역유료일사중요적연구발현。장기지속적쌍련산염류약물치료회제고환자비전형고골골절적풍험。재골절고풍험적절경후환자중，특립파태화적낙새맥연합치료조여량약분별단용조상비，연합치료조환자적골밀도명현증가。목전，일사치료골질소송신적책략정처우불동적연구계단，여조직단백매K억제제、중조갑상방선격소。
During the past 1 to 2 years,there're some important discoveries in the domain of postmenopausal osteoporosis. Study showed the risk for vertebral fractures became obviously higher for women who were continuously taking Azole phosphonic acid drugs. In post-menopausal patients with high risk of fracture,by comparing with the combined medication group using Teriparatide and Prolia with the separate medication group,it was found out that bone mineral density in patients with combined medication was obviously in-creased. Some new treatment strategy for osteoporosis is now in different stages of development,e. g. ,cathepsin K inhibitor and recombi-nant parathyroid hormone.